Clearance Rates
RAPID RELIEF, RELIABLE CONTROL EVERYWHERE1-4
Starting as early as 2 or 4 weeks*
*Statistical significance achieved as early as Week 4 for IGA Success in both DERMIS studies and as early as Week 2 for I-IGA Success and WI-NRS Success in DERMIS-2.1,2
See the results at Week 8
Primary
Endpoint
IGA Success†
Key Secondary
Endpoint
I-IGA Success‡
~40% of patients achieved IGA Success at Week 8
(Clear/Almost Clear + ≥2-grade improvement)1,2
§P<0.0001 vs vehicle.
IGA Success rates at Week 8 were consistent regardless of baseline involvement
(mild, moderate, severe)2
~60% mean PASI improvement at just 8 weeks2
†IGA Success = Achievement of an IGA Score of Clear/Almost Clear and a ≥2-grade improvement from baseline.
‡I-IGA Success = Achievement of an I-IGA Score of Clear/Almost Clear and a ≥2-grade improvement from baseline.
PASI = Psoriasis Area and Severity Index.
~70% of patients achieved I-IGA Success at Week 8
(Clear/Almost Clear + ≥2-grade improvement)1,2
ǁP=0.0001 vs vehicle.
¶P<0.0001 vs vehicle.
#P<0.01 vs vehicle.
Clinical trials for ZORYVE were the first and only Phase 3 trials to evaluate I-IGA Success with topical therapy for plaque psoriasis.
†IGA Success = Achievement of an IGA Score of Clear/Almost Clear and a ≥2-grade improvement from baseline.
‡I-IGA Success = Achievement of an I-IGA Score of Clear/Almost Clear and a ≥2-grade improvement from baseline.